MarketPulse

clinical evidence

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bbb National Programs

J&J Vision Care Ordered to Modify ACUVUE Claims in NAD Ruling

NAD supports J&J's 'MAX comfort' claim for ACUVUE Oasys Max but recommends discontinuing superiority claims versus DAILIES TOTAL1 due to insufficient evidence.
JNJALCregulatory complianceclinical evidence
BenzingaBenzinga··Vandana Singh

Natera Positioned to Capture $20B MRD Market as Testing Adoption Accelerates

William Blair initiates Natera coverage, citing $1B MRD revenue in 2025 with 40%+ growth expected in 2026 as penetration rises.
NTRAmarket opportunitycompetitive advantage
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Philips CMO Joins MDIC Board to Strengthen FDA-Industry Medical Device Innovation

Philips appoints Chief Medical Officer Dr. Carla Goulart Peron to MDIC board, strengthening industry influence over FDA medical device regulatory standards.
PHGhealthcare technologyregulatory approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Collegium to Showcase Real-World Pain Drug Data at 2026 Medical Conference

Collegium Pharmaceutical to present real-world clinical data on pain medication BELBUCA at major medical conference in March 2026.
COLLclinical evidenceCollegium Pharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Corcept Therapeutics Faces Class Action Over Relacorilant Clinical Evidence Claims

Corcept Therapeutics faces class action lawsuit for allegedly misleading statements about relacorilant's clinical evidence. FDA rejected the drug application, causing stock to plummet 50%.
CORTclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Bernstein Liebhard Llp

Law Firm Initiates Class Action Against Corcept Therapeutics Over Relacorilant Claims

Law firm Bernstein Liebhard files class action lawsuit against Corcept Therapeutics for alleged material misrepresentations about relacorilant drug clinical evidence.
SMRCORTsecurities fraudclass action lawsuit